The largest database of trusted experimental protocols

Abi prism 7900 ht sequence detector system

Manufactured by Thermo Fisher Scientific
Sourced in United States

The ABI/Prism 7900 HT Sequence Detector System is a real-time PCR instrument designed for quantitative gene expression analysis. It utilizes a 96-well plate format and can perform up to 384 reactions simultaneously. The system is capable of detecting and quantifying target DNA sequences in real-time during the PCR amplification process.

Automatically generated - may contain errors

18 protocols using abi prism 7900 ht sequence detector system

1

Quantitative Gene Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Total RNA was extracted from the cells using RNeasy micro kits (Qiagen, Hilden, Germany). Complementary DNA was synthesized using SuperScript VILO (Life Technologies). Gene expression levels were quantified by real‐time PCR assay with TaqMan probes and TaqMan universal PCR master mix (Life Technologies) on an ABI Prism 7900HT Sequence Detector System (Life Technologies). The level of each gene expression was normalized to that of β glucuronidase (GusB). All of the TaqMan probes for real‐time PCR are listed in Table S5 in Supporting Information.
+ Open protocol
+ Expand
2

Quantifying Muscle Atrophy Signaling Genes

Check if the same lab product or an alternative is used in the 5 most similar protocols
TaqMan-based qPCR reactions were performed using the ABI PRISM 7900HT Sequence Detector System (Life Technologies, Carlsbad, CA, USA) together with commercially available gene expression assays. The probes corresponding to the following genes involved in signaling of muscle atrophy were tested: ubiquitin-ligase atrogin-1(Atrogin-1, Mm00499523_m1, Life Technologies), ubiquitin-ligase muscle ring finger (MuRF)-1 (Murf-1, Mm01185221_m1, Life Technologies), FoxO1 (Foxo1, Mm00490671_m1, Life Technologies), and FoxO3 (Foxo3, Mm01185722_m1, Life Technologies). The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (Gapdh, Mm99999915_g1, Life Technologies) served as the endogenous control for the mRNA gene [46 (link),47 (link)]. Reactions were run in duplicates, and mRNA data were collected and subsequently analyzed using the sequence detection system relative quantification software version 2.4 (Applied BioSystems, Waltham, MA, USA), in which the comparative CT method (2−ΔΔCT) for relative quantification was employed [48 (link)].
+ Open protocol
+ Expand
3

Quantitative Analysis of Muscle Atrophy Genes

Check if the same lab product or an alternative is used in the 5 most similar protocols
A single RT was performed from which all the target genes of the study were analyzed. Firststrand cDNA was generated from mRNA using oligo(dT) 12-18 primers and the Super-Script III reverse transcriptase following the manufacturer's instructions (Life technologies). TaqMan based qPCR reactions were performed using the ABI PRISM 7900HT Sequence Detector System (Life technologies) together with commercially available gene expression assays. The probes corresponding to the following genes involved in proteolytic system were tested: murf-1 (Rn00590197_m1, Life technologies), atrogin-1 (Rn00591730_m1, Life technologies), and trim32 (Rn01764787_m1, Life technologies). The housekeeping gene gapdh (Rn01775763_g1, Life technologies) served as the endogenous control for mRNA gene expression. Reactions were run in triplicates, and mRNA data were collected and subsequently analyzed using the Expression Suite software v1.1 (Applied Biosystems, Foster City, CA, USA), in which the comparative C T method (2 -∆∆CT ) for relative quantification was employed. Results are shown as the relative expression of that in the non-cachexia control group, which was set to equal to 1.
+ Open protocol
+ Expand
4

Quantitative RT-PCR and IHC Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
qRT-PCR was carried out on the ABI/Prism 7900 HT Sequence Detector System (Applied Biosystems, Foster City, CA, USA), using a pre-PCR step of 10 min at 94.5 °C, followed by 40 cycles of 30 s at 97 °C and 60 s at 59.7 °C. TaqMan Arrays' 384 wells are pre-loaded with TaqMan Gene Expression Assays. Each TaqMan Array evaluates two cDNA samples in triplicate generated in a reverse transcription step using random primers. Selected Taqman assays for GC and CEACAM1 were GC-Hs00167096_m1 and CEACAM1-Hs00266109_m1 by Applied Biosystems. Values relative to the 18s housekeeping gene were used to normalise the data. A mix composed of RNA samples, obtained from the five typical tumours studied in the expression profiling experiment, was used as a calibrator. For each reaction, 100 ng of cDNA was added to 100 μl of reaction mix containing 50 μl of TaqMan PCR Mastermix 2x No UNG (Applied Biosystems) and loaded into each sample-loading port of 384-well TaqMan Low Density Arrays.
Immunohistochemistry (IHC) was performed according to the standard operating procedures applied at the Division of Pathology. Anti-GC and anti-CEACAM1 antibodies were used according to the following specifications: anti-GC dilution 1 : 200 (cod. HPA001526; Sigma-Aldrich Corp., St Louis, MO, USA); anti-CEACAM1 dilution 1 : 100 (cod. ab49510-100, clone 29H2; Abcam, Cambridge, UK).
+ Open protocol
+ Expand
5

Quantifying Gene Expression in Oligodendrocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The corpus callosum was micro-dissected as described above and RNA was extracted with RNeasy Micro Kit (Qiagen). Primary OPCs were collected in 350ul RLT buffer per 60mm dish and extracted in a manner similar to tissue. Total RNA (0.5–1 ug) was used to synthesize cDNA using SuperScript III First strand synthesis system (Life Technologies) or iScript synthesis kit (BioRad) in a 20ul reaction. Primer sequences are provided in Table S1. qPCR was carried out using diluted cDNA with SYBR Green qPCR mix (Sigma-Aldrich or GeneCopoiea) in 20–25 ul reactions a 96 well spectrofluorometric thermal cycler (ABI Prism 7900 HT Sequence Detector System; Applied Biosystems). Cycling conditions were as follows: Stage 1 95°C 10 min, Stage 2 40 cycles 95°C 45 s, 56–60°C 45 s, 72°C 45 s. Baseline values lie between cycles 8 and 15. Mean fold gene expression normalized against beta-actin was calculated with ABI software with the 2 (Delta Delta CT) Method. Data are expressed as mean fold change ± SEM with respect to reference control group.
+ Open protocol
+ Expand
6

Retrospective Pathology Review of DLBCL

Check if the same lab product or an alternative is used in the 5 most similar protocols
A retrospective central pathologic review was conducted by a core lab (Phenopath Laboratories, Seattle, WA). Cases with discordant pathology were adjudicated by R. Gascoyne, MD, University of British Columbia, Vancouver, Canada. Immunohistochemistry was performed for pathologic disease confirmation, DLBCL subtype determination, and CD40 expression. The Hans classification method [12 (link)] was used to classify DLBCL subtypes. Immunohistochemistry stains included antibodies against CD20, CD10, Bcl-6, MUM1, Ki67, and CD40. Fcγ receptor IIa and IIIa polymorphism analyses were conducted by W. Weng, MD, Stanford University, Stanford, CA, using the TaqMan technology on an ABI Prism 7900HT Sequence Detector System (Applied Biosystems) as previously described [13 (link)].
+ Open protocol
+ Expand
7

Genotyping FcγR Polymorphisms Using TaqMan

Check if the same lab product or an alternative is used in the 5 most similar protocols
Germline DNA samples were genotyped at Stanford University (Pegram laboratory) for three SNPs in the FcγR genes as follows: FCGR3A V158F (rs396991), FCGR2A R131H (rs1801274), and FCGR2B I232T (rs1050501). For each SNP, genotyping was performed with TaqMan real-time PCR assays (Applied Biosystems, Foster City, CA). FCGR3A V158F and FCGR2A R131H were Taqman assays on demand (C-25815666-10 and C-9077561-20, respectively). The FCGR2B I232T polymorphism was determined using a custom TaqMan SNP Genotyping Assay (Applied Biosystems) with the following primers: sense 5′-CCTAGCTCCCAGCTCTTCAC-3′ and antisense 5′-CCACTACAGCAGCAACAATGG-3′. TaqMan reactions were set up in 25μL volumes as per the manufacturer's instructions (Applied Biosystems, Foster City, CA), with 10ng DNA. Thermal cycling conditions were initial denaturation step at 95°C for 10 minutes, followed by 50 cycles of denaturation at 92°C for 15 seconds, and annealing/extension step at 60°C for 1 minute. All samples were run in duplicate. Each reaction plate included a triplicate non-template control and internal positive controls. Allelic discrimination was performed with an ABI Prism 7900HT Sequence Detector system using SDS 1.2.3 Software (Applied Biosystems, Foster City, CA). Human DNA specimens (NA00131, NA00607, NA00893) purchased from the Coriell Institute for Medical Research were used as positive controls for each SNP.
+ Open protocol
+ Expand
8

Quantifying Drosophila Larval Transcripts

Check if the same lab product or an alternative is used in the 5 most similar protocols
Larval brains were collected and homogenized using pestles. RNA extraction was performed using RNeasy Mini Kit (Qiagen, 74,104). The concentration of extracted RNA was measured using the NanoDrop 1000 Spectrophotometer. Complementary DNA (cDNA) was synthesized from RNA through reverse transcription, according to the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, 11,754,050). Real-time PCR was carried out on the ABI/Prism 7900 HT Sequence Detector System (Applied Biosystems, Carlsbad, CA, USA) using primers that were designed from Universal Probe Library (UPL) Roche. These reactions were performed by the Cogentech qPCR service facility (Milan, Italy). Alternatively, samples were analyzed using StepOnePlus™ Real-Time PCR Systems (Applied Biosystems, Carlsbad, CA, USA), Fast SYBR Green Master Mix (Thermo Fisher Scientific, 4,385,617) and primers selected from http://www.flyrnai.org/flyprimerbank [50 (link)]. Amplicon expression in each sample was normalized to RpL32 mRNA content. Primers sequences are listed in Table S2.
+ Open protocol
+ Expand
9

Quantitative Gene Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Total RNA was extracted using Trizol (Invitrogen) followed by DNAse treatment. RNA abundance was determined after Reverse Transcription (RT) and either standard or quantitative PCR (qPCR) techniques [30 (link)]. cDNA synthesis was performed using 500 ng of total RNA with a High Capacity cDNA Archive Kit (Applied Biosystems/Life Technologies, Grand Island, NY). PCR reactions were performed with the GeneAmp PCR System 9700 using the AmpliTaq Gold DNA Polymerase (both Applied Biosystems). Quantitative PCR reactions were performed with the ABI PRISM 7900HT Sequence Detector System using the core reagent kit and the SYBR Green PCR Master Mix (all Applied Biosystems) in a 384 well plate format. Primers sequences have been previously described [26 (link)].
+ Open protocol
+ Expand
10

Cardiac Gene Expression Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Total ribonucleic acid (RNA) was extracted from the cardiac tissues using TRIzol reagent (Invitrogen, USA) and reverse-transcribed into complementary DNA using the PrimeScript RT Reagent Kit (Takara Biotechnology, China), according to the manufacturer's instructions. The messenger RNA levels of the target genes were quantified using SYBR Green Master Mix (Takara Biotechnology), with the ABI PRISM 7900HT Sequence Detector System (Applied Biosystems, USA). Each reaction was performed twice, and the changes in the relative gene expression, which were normalized to glyceraldehyde 3-phosphate dehydrogenase levels, were determined using the relative threshold cycle method. The primer sequences are shown in Table 1.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!